Regeneron CEO Schleifer bags massive $135M payday after 2020 pandemic wins

Regeneron Pharmaceuticals solidified its position in the COVID-19 fight last year with an emergency nod for its antibody cocktail of casirivimab and imdevimab—one of the few coronavirus treatments to win the FDA's blessing.

For helming the ship, the company awarded CEO Len Schleifer, M.D., Ph.D., a staggering $135.35 million in 2020 pay. His salary came in at about $1.5 million, and the CEO collected another $3.5 million in cash incentive pay.